Careium AB AI Stock Analysis
Want to see SE:CARE full AI Analyst Report?
Careium AB (CARE) AI Stock Analysis
Careium AB
(Nasdaq OMX AB:CARE)
The score is driven primarily by improving financial performance (profitability rebound and healthier leverage), supported by a positive technical trend with moderate momentum. Valuation is the main limiter, as a ~19 P/E with no dividend yield looks only fair relative to modest margins and uneven cash-flow consistency.
Careium AB (CARE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 734.65M
- Dividend Yield
- ―
- Average Volume (3M)
- 16.32K
- Price to Earnings (P/E)
- 14.8
- Beta (1Y)
- 0.39
- Revenue Growth
- 12.86%
- EPS Growth
- 18.01%
- Country
- Sweden
- Employees
- 613
- Sector
- General
- Sector Strength
- 55
- Industry
- Security & Protection Services
Careium AB Business Overview & Revenue Model
Company Description
Careium AB (Publ), established in 1974 and headquartered in Malmö, Sweden, specializes in providing technologically advanced care solutions across numerous European nations, including Sweden, Norway, the United Kingdom, and the Netherlands. Their ext...
How the Company Makes Money
Careium makes money by selling and supporting telecare offerings that combine hardware and ongoing service delivery. Revenue is typically generated through: (1) service fees for operating telecare solutions, which can include hosting/operating the pl...
Careium AB Financial Statement Overview
Summary
Financials show a clear rebound with positive operating profit and net income plus renewed TTM revenue growth (~5%). Balance sheet leverage is manageable and improving (debt-to-equity ~0.29), but profitability remains modest (net margin ~4%) and cash flow consistency is a key risk given uneven cash conversion and prior volatility.
Income Statement
72PositiveBalance Sheet
78PositiveCash Flow
64Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.70M | 854.10M | 870.70M | 824.60M | 725.10M | 587.50M |
| Gross Profit | 419.40M | 375.10M | 373.70M | 340.50M | 273.70M | 240.30M |
| EBITDA | 142.30M | 120.60M | 150.60M | 137.90M | 67.90M | 65.10M |
| Net Income | 50.60M | 35.80M | 58.40M | 37.90M | -8.60M | 4.70M |
Balance Sheet | ||||||
| Total Assets | 1.14B | 1.09B | 1.05B | 961.40M | 992.10M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 28.00M | 54.90M | 31.90M | 31.50M | 39.90M | 142.50M |
| Total Debt | 219.20M | 209.70M | 196.80M | 225.30M | 322.70M | 292.30M |
| Total Liabilities | 424.70M | 407.40M | 371.40M | 361.90M | 425.50M | 500.20M |
| Stockholders Equity | 717.70M | 681.50M | 678.20M | 599.50M | 566.60M | 551.50M |
Cash Flow | ||||||
| Free Cash Flow | 63.50M | 51.30M | 36.90M | 61.90M | -87.10M | -70.90M |
| Operating Cash Flow | 131.90M | 143.40M | 92.90M | 111.90M | -21.10M | -19.80M |
| Investing Cash Flow | -97.10M | -102.20M | -56.00M | -50.00M | -68.70M | -163.70M |
| Financing Cash Flow | -37.50M | -13.70M | -39.60M | -69.70M | -15.10M | 291.00M |
Careium AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARE, the sentiment is Positive. The current price of 30.20 is above the 20-day moving average (MA) of 28.92, above the 50-day MA of 27.97, and above the 200-day MA of 25.50, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 61.46 is Neutral, neither overbought nor oversold. The STOCH value of 91.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CARE.
Careium AB Peers Comparison
Overall Rating
SE:DEDI72Outperform
SE:CARE69Neutral
SE:PTRK59Neutral
SE:NNH51Neutral
SE:BOUL41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | SEK 629.51M | 12.50 | ― | 2.78% | 9.56% | 20.95% | |
| 69Neutral | SEK 734.65M | 14.80 | ― | ― | 12.86% | 18.01% | |
| 59Neutral | SEK 178.06M | -2.04 | ― | ― | -10.30% | -11.59% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | SEK 94.17M | 20.54 | ― | 1.64% | 2.70% | -43.94% | |
| 41Neutral | SEK 49.51M | -2.84 | -58.52% | ― | -16.09% | 78.68% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CARE | Careium AB | 30.20 | 5.40 | 21.77% | |
| SE:MVIR | Medivir | 1.13 | 0.70 | 160.69% | |
| SE:BOUL | Boule Diagnostics AB | 1.27 | -4.21 | -76.73% | |
| SE:NNH | New Nordic Healthbrands AB | 15.20 | -6.64 | -30.42% | |
| SE:DEDI | Dedicare AB | 63.00 | 20.26 | 47.39% | |
| SE:PTRK | Physitrack Limited | 10.95 | -3.85 | -26.01% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
